Endocrine, Journal Year: 2024, Volume and Issue: 85(1), P. 222 - 232
Published: Feb. 20, 2024
Language: Английский
Endocrine, Journal Year: 2024, Volume and Issue: 85(1), P. 222 - 232
Published: Feb. 20, 2024
Language: Английский
Current Obesity Reports, Journal Year: 2024, Volume and Issue: 13(3), P. 440 - 460
Published: April 12, 2024
Language: Английский
Citations
6MedComm, Journal Year: 2024, Volume and Issue: 5(8)
Published: July 24, 2024
Metabolic disorders, including obesity, dyslipidemia, diabetes, nonalcoholic fatty liver disease, and metabolic syndrome, are characterized by insulin resistance, abnormalities in circulating cholesterol lipid profiles, hypertension. The most common pathophysiologies of disorders glucose/lipid metabolism dysregulation, inflammatory response, oxidative stress. Although several agents have been approved for the treatment there is still a strong demand more efficacious drugs with less side effects. Natural products critical sources drug research discovery decades. However, usefulness bioactive natural often limited incomplete understanding their direct cellular targets. In this review, we highlight current established emerging molecular mechanisms disorders. We further summarize therapeutic effects underlying on highlights targets, which mainly implicated regulation metabolism, inflammation, Finally, review also covers clinical studies These progresses expected to facilitate application these derivatives development novel against
Language: Английский
Citations
5Cell Metabolism, Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 1, 2024
Language: Английский
Citations
5Cell Metabolism, Journal Year: 2024, Volume and Issue: unknown
Published: Dec. 1, 2024
Language: Английский
Citations
5Endocrine, Journal Year: 2024, Volume and Issue: 85(1), P. 222 - 232
Published: Feb. 20, 2024
Language: Английский
Citations
4